Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
interleukin-2
Biotech
Gilead pays $43.5M for Xilio's early-phase IL-12 prospect
Gilead is bucking the trend in IL-12, entering the space after seeing rivals such as AstraZeneca and Bristol Myers Squibb retreat from the cytokine.
Nick Paul Taylor
Mar 28, 2024 8:08am
Mural wants to paint new picture in IL-2 after Alkermes spinout
Nov 15, 2023 8:56am
Coya deems dementia drug R&D plan 'premature,' switches focus
Jun 12, 2023 9:00am
Neoleukin lays off 70% of staff, hunts for strategic alternative
Mar 9, 2023 5:45am
AstraZeneca deals another blow to IL-12 by dumping gene therapy
Feb 9, 2023 8:15am
Merck KGaA hands over IL-12 cancer med for up to $121M
Jan 3, 2023 2:17pm